UniSa - IRIS Institutional Research Information System

MASARONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.948
NA - Nord America 6.980
EU - Europa 2.371
SA - Sud America 800
Continente sconosciuto - Info sul continente non disponibili 283
AF - Africa 130
OC - Oceania 6
Totale 19.518
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.706
HK - Hong Kong 5.781
SG - Singapore 1.344
IT - Italia 1.012
CN - Cina 668
BR - Brasile 615
VN - Vietnam 476
RU - Federazione Russa 292
UA - Ucraina 194
DE - Germania 169
FR - Francia 158
CA - Canada 130
TR - Turchia 130
IE - Irlanda 127
KR - Corea 111
BD - Bangladesh 108
GB - Regno Unito 90
AR - Argentina 77
SE - Svezia 75
FI - Finlandia 65
IN - India 64
MX - Messico 51
ZA - Sudafrica 43
JP - Giappone 41
IQ - Iraq 36
NL - Olanda 35
EC - Ecuador 33
ID - Indonesia 33
DK - Danimarca 27
PL - Polonia 27
CO - Colombia 22
VE - Venezuela 22
PK - Pakistan 21
ES - Italia 20
IL - Israele 20
AT - Austria 17
CR - Costa Rica 17
JM - Giamaica 17
HN - Honduras 16
UZ - Uzbekistan 15
MA - Marocco 14
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
EG - Egitto 11
GT - Guatemala 9
KE - Kenya 9
LT - Lituania 9
MY - Malesia 9
PS - Palestinian Territory 9
PH - Filippine 8
AL - Albania 7
GR - Grecia 7
KZ - Kazakistan 7
TN - Tunisia 7
AZ - Azerbaigian 6
DZ - Algeria 6
NI - Nicaragua 6
PE - Perù 6
SN - Senegal 6
EU - Europa 5
RO - Romania 5
AU - Australia 4
CG - Congo 4
CL - Cile 4
DO - Repubblica Dominicana 4
JO - Giordania 4
NO - Norvegia 4
OM - Oman 4
SC - Seychelles 4
TT - Trinidad e Tobago 4
UG - Uganda 4
AO - Angola 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CI - Costa d'Avorio 3
ET - Etiopia 3
LY - Libia 3
NP - Nepal 3
PT - Portogallo 3
QA - Qatar 3
UY - Uruguay 3
BB - Barbados 2
BS - Bahamas 2
BZ - Belize 2
CH - Svizzera 2
CW - ???statistics.table.value.countryCode.CW??? 2
EE - Estonia 2
GE - Georgia 2
GP - Guadalupe 2
GY - Guiana 2
IR - Iran 2
LB - Libano 2
LC - Santa Lucia 2
LV - Lettonia 2
MW - Malawi 2
PR - Porto Rico 2
RS - Serbia 2
Totale 19.204
Salva come PNG Salva come JPEG
Città #
Hong Kong 5.770
San Jose 889
Ann Arbor 778
Singapore 659
Ashburn 445
Chandler 362
Princeton 344
Milan 341
Woodbridge 336
Council Bluffs 267
Jacksonville 266
Dallas 262
Houston 189
Beijing 182
New York 145
The Dalles 140
Dublin 123
Ho Chi Minh City 123
Los Angeles 110
Lauterbourg 108
Dong Ket 106
Izmir 106
Wilmington 102
Rome 97
Hanoi 87
Santa Clara 86
Moscow 74
Nanjing 73
São Paulo 68
Andover 63
Munich 57
Naples 55
Boardman 46
Pellezzano 44
Tokyo 39
Denver 33
Memphis 33
Phoenix 33
Montreal 30
Chicago 29
Salerno 29
Brooklyn 28
Atlanta 27
Fairfield 27
Figino 27
Johannesburg 26
Redwood City 26
Changsha 24
Columbus 24
Mexico City 24
Norwalk 24
Orem 24
Hebei 23
Turin 23
Warsaw 23
Frankfurt am Main 22
Shenyang 22
Turku 22
Washington 22
Haiphong 21
North Charleston 21
Rio de Janeiro 21
London 20
Stockholm 20
Amsterdam 18
Chennai 18
Da Nang 18
Seattle 18
Belo Horizonte 17
Jinan 17
Nanchang 17
Toronto 17
Dearborn 16
Dhaka 16
Tashkent 15
Jiaxing 14
Nuremberg 14
San José 14
Buffalo 13
Baghdad 12
Brasília 12
Curitiba 12
Guayaquil 12
Helsinki 12
Manchester 12
Tianjin 12
Copenhagen 11
Guangzhou 11
Ottawa 11
Boston 10
Caracas 10
Charlotte 10
Fisciano 10
Jinju 10
Nürnberg 10
Poplar 10
San Diego 10
City of London 9
Erbil 9
Kingston 9
Totale 14.136
Salva come PNG Salva come JPEG
Nome #
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 785
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 782
Non Alcoholic Fatty Liver: Epidemiology and Natural History 638
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 618
Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study 506
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 448
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 414
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 386
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 355
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 339
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 330
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 322
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 313
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 303
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 275
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 224
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 218
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 204
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 199
The diagnostic conundrum in non-alcoholic fatty liver disease 197
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 196
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 194
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 167
Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study 166
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 165
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 163
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 162
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 159
Coeliac disease and C virus-related chronic hepatitis: a non association 157
Alcoholic Liver Disease and Hepatitis C Chronic Infection 154
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 151
Epidemiology and Natural History of Alcoholic Liver Disease 150
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 149
Adiponectin in hepatology 148
Pharmacotherapy of alcoholic liver disease in clinical practice 147
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 145
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 140
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease 139
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus 139
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 137
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 137
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 136
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 134
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 133
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 133
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 132
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 130
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 128
Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study 128
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 126
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 126
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 126
Viral hepatitis: Milestones, unresolved issues, and future goals 126
Efficacy and Safety of a Polysaccharide-Based Natural Substance Complex in the Treatment of Obesity and Other Metabolic Syndrome Components: A Systematic Review 125
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 125
Metabolic associated steatotic liver disease in renal transplant recipients: a retrospective cohort study 123
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 122
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver 121
HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era 119
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 118
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 117
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 117
Lung ultrasound for diagnosis of pneumonia in emergency department 116
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 115
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 114
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 114
Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: A pilot study 113
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 111
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 111
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 110
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 109
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 109
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System 108
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 107
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 107
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 105
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 105
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 104
Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study 104
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 104
Artificial Intelligence and liver: Opportunities and barriers 102
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. 102
Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis 102
A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 102
Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers 101
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study 100
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 98
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 97
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 97
Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study 95
P. 253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients 93
Corrigendum to “Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)” [Dig Liver Dis 54 (2022) 170–182, (S1590865821002140), (10.1016/j.dld.2021.04.029)] 92
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 92
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. 91
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 90
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 90
Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy 90
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) 90
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention 87
Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle? 86
Totale 17.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.646
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022581 0 0 0 0 10 10 22 31 83 82 80 263
2022/2023918 102 72 54 110 99 189 3 67 135 5 60 22
2023/2024515 35 49 36 24 39 100 26 31 9 19 35 112
2024/20251.585 32 29 23 53 106 165 272 150 284 106 189 176
2025/202611.207 695 2.891 2.923 522 776 366 927 219 392 606 237 653
2026/20271.697 206 206 534 659 92 0 0 0 0 0 0 0
Totale 19.518